# **OIE Reference Laboratory Reports Activities**Activities in 2021

This report has been submitted: 2022-01-18 14:48:53

Name of disease (or topic) for which you are a designated OIE Reference Laboratory:	Avian mycoplasmosis (Mycoplasma gallisepticum)
Address of laboratory:	Pendik Veterinary Control Institute Bati Mah. Yunus Cad. No:2/1 34890 Pendik-ISTANBUL TURKEY
Tel.:	+90-216 390.12.80
Fax:	+90-216 354.76.92
E-mail address:	umit.sevimli@outlook.com
Website:	https://vetkontrol.tarimorman.gov.tr/pendik
Name (including Title) of Head of Laboratory (Responsible Official):	Dr. Fahriye Sarac
Name (including Title and Position) of OIE Reference Expert:	Dr.Umit Sevimli
Which of the following defines your laboratory? Check all that apply:	Governmental

## ToR 1: To use, promote and disseminate diagnostic methods validated according to OIE Standards

1. Did your laboratory perform diagnostic tests for the specified disease/topic for purposes such as disease diagnosis, screening of animals for export, surveillance, etc.? (Not for quality control, proficiency testing or staff training)

Yes

Diagnostic Test	Indicated in OIE Manual (Yes/No)	Total number of test performed last year	
Indirect diagnostic tests		Nationally	Internationally
iELISA	Yes	0	0
RSA	Yes	0	0
Direct diagnostic tests		Nationally	Internationally
Bacteriological culture	Yes	484	
PCR Yes		-	
Real-Time PCR	No	83	

ToR 2: To develop reference material in accordance with OIE requirements, and implement and promote the application of OIE Standards.

To store and distribute to national laboratories biological reference products and any other reagents used in the diagnosis and control of the designated pathogens or disease.

2. Did your laboratory produce or supply imported standard reference reagents officially recognised by the OIE?

No

3. Did your laboratory supply standard reference reagents (non OIE-approved) and/or other diagnostic reagents to OIE Member Countries?

Yes

Type of reagent available	Related diagnostic test	Produced/ provide	Amount supplied nationally (ml, mg)	Amount supplied internationally (ml, mg)	No. of recipient OIE Member Countries	Region of recipients
Mycoplasma gallisepticum S6 strain DNA	PCR	Produced, 500ul	200ul	200ul	2	
Mycoplasma gallisepticum S6 strain	Culture	Provided	Lyophilized 2ml	Lyophilized 2ml	2	Africa  America  S  Asia  and  Pacific  Europe  Middle  East
M.gallisepticum rapid serum agglutitation antigen.	RSA	Produced	1160 ml			Africa America s Asia and Pacific Europe Middle East
M.gallisepticum reverse- forward primers(OIE,2021)	PCR	Provided	100 ul			□Africa □America s □Asia and Pacific □Europe □Middle East

4. Did your laboratory produce vaccines?

No

5. Did your laboratory supply vaccines to OIE Member Countries?

# ToR 3: To develop, standardise and validate, according to OIE Standards, new procedures for diagnosis and control of the designated pathogens or diseases

6. Did your laboratory develop new diagnostic methods validated according to OIE Standards for the designated pathogen or disease?

No

7. Did your laboratory develop new vaccines according to OIE Standards for the designated pathogen or disease?

No

## ToR 4: To provide diagnostic testing facilities, and, where appropriate, scientific and technical advice on disease control measures to OIE Member Countries

8. Did your laboratory carry out diagnostic testing for other OIE Member Countries?

No

9. Did your laboratory provide expert advice in technical consultancies on the request of an OIE Member Country?

Yes

Name of the OIE Member Country receiving a technical consultancy	Purpose	How the advice was provided
COLOMBIA	Diagnostic methods for mycoplasma diseases	By e-mail
FINLAND	Mycoplasma gallisepticum RSA test validation	By e-mail
SPAIN	Avian mycoplasma detection methods	By e-mail
NIGERIA	Technical advice establishment of mycoplasma laboratory design	By e-mail

# ToR 5: To carry out and/or coordinate scientific and technical studies in collaboration with other laboratories, centres or organisations

10. Did your laboratory participate in international scientific studies in collaboration with OIE Member Countries other than the own?

# ToR 6: To collect, process, analyse, publish and disseminate epizootiological data relevant to the designated pathogens or diseases

11.	Did	your	Laboratory	collect ep	izootiologica	l data	relevant to	international	disease (	control?

Yes

If the answer is yes, please provide details of the data collected:

In accordance with the legislation of our Ministry of Agriculture and Forest, routine controls of Hatchery and Poultry Breeding Farms in terms of Mg and Mm are carried out in 6 months.

12. Did your laboratory disseminate epizootiological data that had been processed and analysed?

Yes

If the answer is yes, please provide details of the data collected:

Notification is made to the Ministry of Agriculture and Forestry.

## 13. What method of dissemination of information is most often used by your laboratory? (Indicate in the appropriate box the number by category)

a) Articles published in peer-reviewed journals: 1

Gurbilek S E, Sevimli U, Tel O Y. The Evaluation of Humoral Immune Response to Contagious Bovine Pleuropneumonia in Cattle with Respiratory Disorders by Western Blot Technique, Competitive Enzyme Linked Immunosorbent Assay and Complement Fixation Test. Dicle Üniv Vet Fak Derg 2021;14(2):113-117,e-ISSN:1308-0679

- b) International conferences: 0
- c) National conferences: 0
- d) Other:

(Provide website address or link to appropriate information) 0

# ToR 7: To provide scientific and technical training for personnel from OIE Member Countries

To recommend the prescribed and alternative tests or vaccines as OIE Standards

14. Did your laboratory provide scientific and technical training to laboratory personnel from other OIE Member Countries?

# ToR 8: To maintain a system of quality assurance, biosafety and biosecurity relevant for the pathogen and the disease concerned

15. Does your laboratory have a Quality Management System?

Yes

Quality management system adopted	Certificate scan (PDF, JPG, PNG format)
EN ISO/IEC 17025 TURKAK	Accreditation certificate.pdf2021.pdf

16. Is your quality management system accredited?

Yes

Test for which your laboratory is accredited	Accreditation body
Mycoplasma gallisepticum isolation&identification	TURKAK
Mycoplasma gallisepticum agent detection- Real Time PCR	TURKAK

17. Does your laboratory maintain a "biorisk management system" for the pathogen and the disease concerned?

Yes

(See Manual of Diagnostic Tests and Vaccines for Terrestrial Animals, Chapter 1.1.4)

#### ToR 9: To organise and participate in scientific meetings on behalf of the OIE

18. Did your laboratory organise scientific meetings on behalf of the OIE?

No

19. Did your laboratory participate in scientific meetings on behalf of the OIE?

No

ToR 10: To establish and maintain a network with other OIE Reference Laboratories designated for the same pathogen or disease and organise regular inter-laboratory proficiency testing to ensure comparability of results

20. Did your laboratory exchange information with other OIE Reference Laboratories designated for the same pathogen or disease?

No

21. Was your laboratory involved in maintaining a network with OIE Reference Laboratories designated for the same pathogen or disease by organising or participating in proficiency tests?

No

22. Did your laboratory collaborate with other OIE Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest?

No

### ToR 11: To organise inter-laboratory proficiency testing with laboratories other than OIE Reference Laboratories for the same pathogens and diseases to ensure equivalence of results

23. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than OIE Reference Laboratories for the same disease?

Yes

Note: See Interlaboratory test comparisons in: Laboratory Proficiency Testing at: http://www.oie.int/en/our-scientific-expertise/reference-laboratories/proficiency-testing see point 1.3

Purpose for inter-laboratory test comparisons <sup>1</sup>	No. participating laboratories	Region(s) of participating OIE Member Countries
M. Agalactiae Ab Detection ELISA(participate)	5	□Africa □Americas □Asia and Pacific ⊠Europe □Middle East
M. Agalactiae PCR Detection (participate)	5	□Africa □Americas □Asia and Pacific ⊠Europe □Middle East
Mccp PCR (organised 2020, results in 2021)	4	□Africa □Americas □Asia and Pacific □Europe □Middle East

#### ToR 12: To place expert consultants at the disposal of the OIE

24. Did your laboratory place expert consultants at the disposal of the OIE?

- 25. Additional comments regarding your report:
- -Mycoplasma gallisepticum extracted DNA, Mycoplasma synoviae extracted DNA, Mycoplasma gallisepticum S6 strain, Mycoplasma synoviae WVU 1853 strain were sent to the Department of Veterinary Microbiology Faculty of Veterinary Medicine, University of Ilorin, Nigeria
- "Mycoplasma synoviae Active Surveillance Program in Poultry Breeding Farms" has been planned in order to determine the status of Mycoplasma synoviae in Poultry Breeding Farms (meat and layers) across the country. Tracheal swab, cloacal swab and serum samples were collected from Poultry Breeding Farms. Real Time PCR for cloacal and tracheal swab samples, iELISA and RSA for serum samples have been performed by our laboratory.
- Avian Mycoplasma isolation and identification training was given to a Phd student at Harran University Microbiology Department and Mycoplasma gallisepticum S6 strain, Mycoplasma synoviae WVU 1853 strain and their extracted DNA were provided to be used in her Phd study.
- -Mycoplasma gallisepticum S6 strain and Mycoplasma synoviae WVU 1853 were provided to a PhD student working at Bornova Veterinary Control Institute to be used in his Phd study.
- Mg (OIE,2021), Ms (OIE,2021) and Mycoplasma Genus PCR forward and reverse primers were provided to Bornova Veterinary Control Institute Viral Vaccine Control Department.
- -Otovaccine was prepared against CCPP disease in a goat farm in Adana province. The sterility and safety tests were performed, then the prepared vaccine was used to the infected herd.
- -Technical training was continued for the new veterinarian who started working in our laboratory.
- Within the scope of the project titled "Development of Inactive Covid-19 Vaccine" the presence of Mycoplasma spp. as contaminant were investigated in some cell culture ingredients, in cell cultures by culture method and Mycoplasma genus specific PCR in our laboratory.
- Participation to the proficiency tests were carried out in Contagious agalactia Ab Detection and Contagious agalactia PCR Detection organised by APHA OIE Reference Laboratory.